Skip to main content
Home > The Daily Extra > Company News

Chronological Index of BioCentury Extra, The Daily News: Company News

BioCentury Extra, The Daily News Current Issue
  • COMPANY NEWS: ThromboGenics resubmits ocriplasmin BLA

    As expected, ThromboGenics N.V. (Euronext:THR) resubmitted a BLA for ocriplasmin to treat symptomatic vitreomacular adhesion. The company withdrew the application in February after receiving notice that FDA intended to …

    Published on 4/17/2012
  • COMPANY NEWS: AstraZeneca, Conformetrix in discovery deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN) and Conformetrix Ltd. (Manchester, U.K.) partnered to use Conformetrix's NMR-based technology to enhance lead discovery and hit identification in AstraZeneca's preclinical pipeline. …

    Published on 4/16/2012
  • COMPANY NEWS: Celltrion submits application to EMA for biosimilar infliximab

    Celltrion Inc. (KOSDAQ:068270) submitted a regulatory application to EMA for a biosimilar version of autoimmune drug infliximab. According to EMA, this is the first application submitted for a biosimilar mAb. The …

    Published on 4/16/2012
  • COMPANY NEWS: Express Scripts launches tool to predict, prevent non-adherence

    Pharmacy benefit manager Express Scripts Inc. (NASDAQ:ESRX) launched a tool to improve drug adherence by identifying patients who are most likely to stop taking their medication. The tool, called ScreenRx, sorts through…

    Published on 4/16/2012
  • COMPANY NEWS: Halozyme, Baxter off as FDA wants more HyQvia data

    Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) and Baxter International Inc. (NYSE:BAX) slid on Monday after FDA told the partners it needs additional information before the agency can complete the review of HyQvia …

    Published on 4/16/2012
  • COMPANY NEWS: IQWiG finds benefit for Edurant, none for Eviplera

    The German Institute for Quality and Efficiency in Health Care (IQWiG) issued preliminary benefit assessments of HIV drugs Edurant rilpivirine and Eviplera emtricitabine/tenofovir/rilpivirine compared with Sustiva …

    Published on 4/16/2012
  • COMPANY NEWS: IQWiG: Nulojix benefits kidney transplant patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) said Nulojix belatacept from Bristol-Myers Squibb Co. (NYSE:BMY) provides a "small degree" of additional benefit compared with generic cyclosporine …

    Published on 4/16/2012
  • COMPANY NEWS: Piramal to acquire Bayer's PET tracer assets

    The Piramal Imaging S.A. subsidiary of Piramal Healthcare Ltd. (BSE:500302; NSE:PIRHEALTH) will acquire worldwide rights to the PET imaging tracer assets of Bayer AG (Xetra:BAYN). The deal includes Bayer's florbetaben, …

    Published on 4/16/2012
  • COMPANY NEWS: Vanda in-licenses Lilly's NK1 receptor antagonist

    Eli Lilly and Co. (NYSE:LLY) granted Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) exclusive, worldwide rights to develop and commercialize VLY-686, a small molecule neurokinin 1 (NK1) substance P receptor (TACR1) antagonist…

    Published on 4/16/2012
  • COMPANY NEWS: Addex restructuring

    Addex Therapeutics (SIX:ADXN) said late Friday it plans to restructure and reduce headcount by up to 28 (33%) from about 85 to reduce costs. Addex said it will disclose further details on the restructuring after a …

    Published on 4/13/2012
  • COMPANY NEWS: GE, Clino to develop tau imaging tracers for AD

    GE Healthcare's Medical Diagnostics business partnered with Clino Ltd. (Sendai, Japan) to discover and develop in vivo PET imaging tracers to detect the accumulation of microtubule-associated protein tau (MAPT; tau; …

    Published on 4/13/2012
  • COMPANY NEWS: Algeta exercises option to co-promote Alpharadin

    Algeta ASA (OSE:ALGETA) exercised an option under a 2009 deal with Bayer AG (Xetra:BAYN) to co-promote cancer compound Alpharadin in the U.S. There was no payment associated with exercising the option. Algeta is now …

    Published on 4/12/2012
  • COMPANY NEWS: AnGes, BioLeaders to develop oral hypertension vaccine

    AnGes MG Inc. (Tokyo:4563) and BioLeaders Corp. Co. Ltd. (Daejeon, South Korea) partnered to develop an oral DNA vaccine to treat hypertension. The vaccine will target the angiotensin II type 1 (AT1) receptor (AGTR1) …

    Published on 4/12/2012
  • COMPANY NEWS: Bayer seeks expansion of EU label for Xarelto

    Bayer AG (Xetra:BAYN) submitted an MAA to EMA for oral Xarelto rivaroxaban to treat pulmonary embolism (PE) and to prevent recurrent deep vein thrombosis (DVT) and PE. Bayer is seeking approval for the direct Factor Xa …

    Published on 4/12/2012
  • COMPANY NEWS: Ventana to develop companion diagnostic for Adcetris

    Seattle Genetics Inc. (NASDAQ:SGEN) and Millennium Pharmaceuticals Inc. partnered with Ventana Medical Systems Inc. to develop and commercialize a companion diagnostic for cancer drug Adcetris brentuximab vedotin. The …

    Published on 4/12/2012
  • COMPANY NEWS: FDA committee to discuss Xarelto for ACS

    FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on May 23 to discuss an sNDA from Johnson & Johnson (NYSE:JNJ) for Xarelto rivaroxaban to reduce secondary cardiovascular events in patients with acute …

    Published on 4/11/2012
  • COMPANY NEWS: Mymetics names Pickering CEO, Henney chairman

    Vaccine company Mymetics Corp. (OTCBB:MYMX) hired Grant Pickering as president, CEO and a director, and appointed Christopher Henney as chairman. The pair replaces Jacques-Francois Martin, who was Mymetics' CEO and …

    Published on 4/11/2012
  • COMPANY NEWS: Newco NexDx debuts

    Diagnostics company NexDx Inc. (San Diego, Calif.) made its public debut on Wednesday with a license from the University of California, San Diego and $500,000 in a series A round from City Hill Ventures. The university …

    Published on 4/11/2012
  • COMPANY NEWS: Quest names Rusckowski CEO

    Quest Diagnostics Inc. (NYSE:DGX) hired Stephen Rusckowski as president, CEO, and a director, effective May 1. Rusckowski, currently CEO of the Philips Healthcare unit of Royal Philips Electronics N.V. (NYSE:PHG; …

    Published on 4/11/2012
  • COMPANY NEWS: NeuroSearch now seeking global Huntexil partner

    NeuroSearch A/S (CSE:NEUR) said it is now seeking a worldwide partnership for Huntexil pridopidine after it was unable to secure a deal that would have excluded European rights to the Huntington's disease product. The …

    Published on 4/10/2012
  • COMPANY NEWS: ViroPharma falls as FDA approves Vancocin generics

    ViroPharma Inc. (NASDAQ:VPHM) fell $6.17 (22%) to $22.44 on Tuesday after FDA approved three generic versions of the company's oral antibiotic Vancocin vancomycin. The agency also denied ViroPharma's Citizen's Petition …

    Published on 4/10/2012
  • COMPANY NEWS: AnaptysBio, Celgene in antibody deal

    AnaptysBio Inc. (San Diego, Calif.) partnered with Celgene Corp. (NASDAQ:CELG) to develop antibodies against cancer and inflammation targets using AnaptysBio's SHM-XEL technology. Celgene will receive worldwide rights …

    Published on 4/9/2012
  • COMPANY NEWS: CommonMind consortium launches

    Takeda Pharmaceutical Co. Ltd (Tokyo:4502) and four organizations launched the CommonMind Consortium to generate and analyze genomic data from patients with neuropsychiatric diseases. Joining Takeda are the not-for-…

    Published on 4/9/2012
  • COMPANY NEWS: Nuron in-licenses preclinical AD vaccine

    Vitruvian Biomedical Inc. (Addison, Texas) granted Nuron Biotech Inc. (Exton, Pa.) exclusive, worldwide rights to develop and commercialize Vitruvian's AB42 vaccine, a DNA vaccine containing a gene fragment that codes …

    Published on 4/9/2012
  • COMPANY NEWS: Optimer removes chairman, reports preliminary revenues

    Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) reported 1Q12 preliminary revenues and said its board removed Chairman Michael Chang and terminated CFO John Prunty and VP Youe-Kong Shue due to "lapses in corporate governance…

    Published on 4/9/2012

< Previous   1  2  3  4  5  6  7  8  9  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.